Issued: 20 December, 2023, London UK

GSK plc Publication of Supplement to Prospectus

GSK plc today announced that the following supplement dated 20^th December, 2023 to the prospectus dated 8^th August, 2023 has been approved by the Financial Conduct Authority and is available for viewing:

GSK plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme

Copies of the supplement to the prospectus and the document incorporated by reference within it have been submitted to the Financial Conduct Authority's National Storage Mechanism (NSM) submission portal via the Electronic Submission System (ESS) and will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

Company Secretary
GSK plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom

[email protected]

Enquiries:

BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENT TO THE PROSPECTUS

Please note that the information contained in the supplement to the prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the supplement to the prospectus is not addressed. Prior to relying on the information contained in the supplement to the prospectus you must ascertain from the supplement to the prospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at https://www.gsk.com/en-gb/company/.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS